This technology includes two chemical compounds that are phosphodiesterase type 5 (PDE5) inhibitors with a benzonaphthyridine derivative chemical scaffold that has not previously been used to treat Alzheimer’s disease or other conditions involving phosphodiesterase PDE5 function.
This technology is an engineered immunomodulatory biomaterial for controlled, localized release of IKKb Inhibitor VIII, synonymously, ACHP, a small molecule inhibitor targeting NF-kB-dependent signaling.
This technology is a small molecule protein therapeutic for systolic heart failure, which improves contractility without an unwanted rise in a patient’s heart rate.
This technology is a targeted anti-tumor agent designed to treat adenoid cystic carcinoma (ACC) by utilizing retinoid receptor modulation to promote cancer cell differentiation and selective cell death.
This technology is a therapeutic targeting neurodegenerative disorders involving small molecules to enhance lipid and cholesterol metabolism in the brain via activation of lecithin cholesterol acyltransferase (LCAT).
This technology identifies SSRI compounds as potential therapies for treating chronic obstructive pulmonary disease (COPD) via inhibition of the proteolytic enzyme metalloproteinase-1 (MMP-1).
This technology describes four chemical compounds that are capable of inhibiting the ID2/VHL interaction for downstream inhibition of tumor growth and angiogenesis.
This technology is a comprehensive compound design and preclinical testing platform that can be used to develop multifunctional drugs for Alzheimer’s disease, and has already led to the development of several promising lead compounds.
This technology is a method of reprogramming cellular metabolism to treat neurodegenerative disorders by downregulating catabolism and upregulating anabolism in cells.
